The Department of Health made the submission, supported the evaluation, waived related cost recovery fees for itself, attended the PBAC meetings at which it has been considered and presumably participated in the discussion, wrote the outcome and managed the listing process. How is this not deeply problematic? …
A deeply problematic situation caused by officials making it up as they go
July 18, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Australia, the US, and their different choices about health system trade-offs
April 17, 2026 - - Latest News -
Why hospitals, and not medicines, dominate America’s health spending gap
April 17, 2026 - - Latest News -
New strategic alliance for Biointelect aims to fast track life sciences innovation
April 17, 2026 - - Latest News -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News -
Why US health spending looks much higher than it really is
April 16, 2026 - - Latest News -
Pharmacy prescribing reform signals shift in NSW primary care with Victoria to follow
April 15, 2026 - - Latest News